03:41 PM EST - Paladin Labs Inc. : announced today that it has entered into an exclusive licensing agreement with Apeiron Biologics AG for APN311, a novel, antibody-based immunotherapy for children with high-risk neuroblastoma. Under the terms of the agreement, Paladin has been granted the exclusive rights to market and sell APN311 in Canada and Sub-Saharan Africa (including South Africa). Further details or financial terms of the transaction were not disclosed. Paladin Labs Inc.
shares T.PLB are trading down $0.47 at $43.98.
